The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

BACKGROUND: Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subset of patients benefits from anti-PD-1/PD-L1 therapies. As a negative regulator...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Ming, Zhang, Jing, Li, Anping, Niu, Mengke, Yan, Yongxiang, Jiao, Ying, Luo, Suxia, Zhou, Pengfei, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885589/
https://www.ncbi.nlm.nih.gov/pubmed/33593403
http://dx.doi.org/10.1186/s13045-021-01045-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885589/
https://www.ncbi.nlm.nih.gov/pubmed/33593403
http://dx.doi.org/10.1186/s13045-021-01045-x

Ejemplares similares